$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

FDA Clears MiniMed Fit Tubeless Pump Seven Days

MiniMed's first tubeless pump doubles the wear time of rival patch pumps on paper and holds half again as much insulin. The clearance came through the FDA's device pathway, it rests on no new outcome trial in the company's announcement, and the launch doesn't reach most patients until spring 2027.

TML Health DeskNov 22, 6:24 AM ET · 2 min read
A glucose sensor worn on the upper arm. MiniMed Fit pairs with two sensors at launch, including Abbott's Instinct. Photo: Thirunavukkarasye-Raveendran / CC BY 4.0, via Wikimedia Commons.
Summary

Cleared in November. On shelves in spring.

Tap a passage. React to the part that matters.

The FDA has cleared MiniMed Fit, a tubeless insulin pump worn for up to seven days, for people with diabetes aged seven and older.

The boundary first. This is a 510(k) clearance, the FDA's device pathway, and the analyst firm BTIG spotted it in the agency's database before MiniMed announced it on November 16. A clearance says the device can be sold for its stated use. It isn't a verdict from a new clinical outcome trial, and MiniMed's announcement doesn't present one. The automation inside the pump, the company's SmartGuard system, already runs in its tubed pumps. What's new is the format, not the algorithm.

The format is the news. Fit is a patch pump worn directly on the body, with no tube and no separate controller, run from an app on iOS or Android. It holds 300 units of insulin, which MiniMed says is 50% more than other tubeless options, and it's cleared for up to twice the wear time of rival patch pumps. The full pump weighs 36 grams and measures 2.46 by 1.68 by 0.6 inches. It works with Humalog, NovoLog and Admelog, charges fully in about 30 minutes, and one charge lasts at least a week. It's waterproof to eight feet for up to one hour and 45 minutes, though glucose readings may not transmit underwater.

The sensor choice matters more than the pump's own clock. At launch, Fit pairs with two sensors: MiniMed's Simplera Sync, worn up to seven days, or Abbott's Instinct, worn up to 15 days. The seven-day figure in the headline is the pump's ceiling. A person who picks the longer sensor still changes the pump on day seven. “Zero interruptions” and “world's first and only” are the company's claims, printed in its own release headline. They aren't FDA findings, and no head-to-head trial against the incumbent tubeless pump backs them.

Access is the practical half of the story. MiniMed will sell Fit through the pharmacy channel rather than the durable medical equipment route, which usually means a pharmacy counter instead of a medical supplier's paperwork. An early customer experience phase comes first, in the company's fiscal fourth quarter of 2027, and the phased United States rollout follows in spring 2027. MiniMed is the diabetes business that separated from Medtronic earlier this year, and it trades on Nasdaq under the ticker MMED.

So the honest summary is narrow. A person with diabetes can't get this pump yet, and the clearance alone doesn't show it controls glucose better than what's already on the market. What it does show is a second tubeless option entering a segment long dominated by one rival, with a longer wear time that, if it holds up in daily use, means fewer pump changes a month. The spring launch is when that claim gets tested.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.